Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma

Published:August 16, 2018DOI:



      We assessed the clinical outcomes of patients with oligoprogressive renal cell carcinoma (mRCC) treated with stereotactic radiosurgery (SRS), stratified by changing or continuing systemic treatment.

      Patients and Methods

      Ninety-five consecutive patients with clear cell mRCC who had undergone SRS to the central nervous system (CNS) or spine during systemic treatment were divided into 3 cohorts: those who continued the same systemic therapy (STAY), those who changed systemic treatment after SRS (SWITCH), and patients with progression outside the SRS sites, who also changed systemic treatment (PD-SYS). The primary outcome was treatment duration after SRS, defined as the interval between SRS and discontinuation of the current systemic therapy for the STAY group and discontinuation of the first subsequent therapy in the SWITCH and PD-SYS groups.


      Local control with SRS was achieved in 85% of the patients. The most common systemic treatment at SRS included anti–vascular endothelial growth factor (67%), mammalian target of rapamycin (14%), and programmed cell death protein 1 inhibitors (9%). The median treatment duration for the STAY group was 5.2 months (95% confidence interval [CI], 3.5-6.9) compared with 5.0 months (95% CI, 4.3-5.7) for the SWITCH group (P = .549) and 3.1 months (95% CI, 1.7-4.5) for the PD-SYS group (P = .07, compared with all other patients). No difference in median overall survival was found for the STAY and SWITCH groups (24.2 vs. 27.1 months; P = .381) but was significantly longer than that for the PD-SYS group (P = .025).


      The decision to continue the same systemic therapy at SRS to treat CNS or spinal lesions did not compromise the clinical outcomes of patients with oligoprogressive mRCC.


      To read this article in full you will need to make a payment


        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
        N Engl J Med. 2007; 356: 115-124
        • Motzer R.J.
        • Hutson T.E.
        • Cella D.
        • et al.
        Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
        N Engl J Med. 2013; 369: 722-731
        • Escudier B.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Sorafenib in advanced clear-cell renal-cell carcinoma.
        N Engl J Med. 2007; 356: 125-134
        • Escudier B.
        • Pluzanska A.
        • Koralewski P.
        • et al.
        Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
        Lancet. 2007; 370: 2103-2111
        • Rini B.I.
        • Escudier B.
        • Tomczak P.
        • et al.
        Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
        Lancet. 2011; 378: 1931-1939
        • Hudes G.
        • Carducci M.
        • Tomczak P.
        • et al.
        Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
        N Engl J Med. 2007; 356: 2271-2281
        • Motzer R.J.
        • Hutson T.E.
        • Glen H.
        • et al.
        Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
        Lancet Oncol. 2015; 16: 1473-1482
        • Choueiri T.K.
        • Escudier B.
        • Powles T.
        • et al.
        Cabozantinib versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1814-1823
        • Motzer R.J.
        • Tannir N.M.
        • McDermott D.F.
        • et al.
        Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.
        N Engl J Med. 2018; 378: 1277-1290
        • Motzer R.J.
        • Escudier B.
        • McDermott D.F.
        • et al.
        Nivolumab versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1803-1813
        • Gerlinger M.
        • Rowan A.J.
        • Horswell S.
        • et al.
        Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
        N Engl J Med. 2012; 366: 883-892
        • Rowe S.P.
        • Tran P.T.
        • Fishman E.K.
        • Johnson P.T.
        Oligoprogression: what radiologists need to know about this emerging concept in cancer therapeutic decision-making.
        Acad Radiol. 2017; 24: 898-900
        • Cheung P.
        Stereotactic body radiotherapy for oligoprogressive cancer.
        Br J Radiol. 2016; 89: 20160251
        • Alongi F.
        • Arcangeli S.
        • Triggiani L.
        • et al.
        Stereotactic ablative radiation therapy in renal cell carcinoma: from oligometastatic to localized disease.
        Crit Rev Oncol Hematol. 2017; 117: 48-56
        • Altoos B.
        • Amini A.
        • Yacoub M.
        • et al.
        Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT).
        Radiat Oncol. 2015; 10: 218
        • Gerszten P.C.
        • Burton S.A.
        • Ozhasoglu C.
        • et al.
        Stereotactic radiosurgery for spinal metastases from renal cell carcinoma.
        J Neurosurg Spine. 2005; 3: 288-295
        • Sheehan J.P.
        • Sun M.H.
        • Kondziolka D.
        • Flickinger J.
        • Lunsford L.D.
        Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control.
        J Neurosurg. 2003; 98: 342-349
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Shaw E.
        • Scott C.
        • Souhami L.
        • et al.
        Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.
        Int J Radiat Oncol Biol Phys. 2000; 47: 291-298
        • Ryu S.
        • Pugh S.L.
        • Gerszten P.C.
        • et al.
        RTOG 0631 phase II/III study of image-guided stereotactic radiosurgery for localized (1-3) spine metastases: phase II results.
        Int J Radiat Oncol Biol Phys. 2011; 81: S131-S132
        • Yomo S.
        • Hayashi M.
        A minimally invasive treatment option for large metastatic brain tumors: long-term results of two-session Gamma Knife stereotactic radiosurgery.
        Radiat Oncol. 2014; 9: 132
        • Yomo S.
        • Hayashi M.
        • Nicholson C.
        A prospective pilot study of two-session Gamma Knife surgery for large metastatic brain tumors.
        J Neurooncol. 2012; 109: 159-165
        • Heng D.Y.
        • Xie W.
        • Regan M.M.
        • et al.
        Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
        J Clin Oncol. 2009; 27: 5794-5799
        • Dabestani S.
        • Marconi L.
        • Hofmann F.
        • et al.
        Local treatments for metastases of renal cell carcinoma: a systematic review.
        Lancet Oncol. 2014; 15: e549-e561
        • Brown P.D.
        • Jaeckle K.
        • Ballman K.V.
        • et al.
        Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial.
        JAMA. 2016; 316: 401-409
        • Kahan B.C.
        • Rehal S.
        • Cro S.
        Risk of selection bias in randomised trials.
        Trials. 2015; 16: 405
        • Ferronika P.
        • Hof J.
        • Kats-Ugurlu G.
        • et al.
        DNA and RNA analysis of intratumour heterogeneity in metastatic clear cell renal cell carcinoma.
        Ann Oncol. 2017; 28: mdx510.001